EichorEICHOR
Study identifier: NCT01270828 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Completed

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia  ·  Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

PhasePhase 3
Planned participants806
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
Where146 locations · 17 countries

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Patients must have pain present for more than 3 months after the healing of the herpes zoster skin rash. * At screening (V1) and enrollment (V2), patients must have a score of greater than or equal to 4 on the Pain Numeric Rating Scale (1 week recall period). * At enrollment (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be greater than or equal to 4. * Male or female of any race, at least 18 years of age, and using appropriate methods of contraception Exclusion Criteria: * Creatinine clearance \<30 mL/min (estimated from serum creatinine). * Skin conditions in the affected dermatome that could alter sensation * Pregabalin use in the last 30 days. Subjects taking pregabalin in the last 30 days should be washed out of pregabalin for at least 30 days prior to screening visit. Patients who had not responded to pregabalin

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (146)

Fundamental ResearchGulf Shores, Alabama, United States
Radiant Research, Inc.Chandler, Arizona, United States
Elite Clinical Studies, LLCPhoenix, Arizona, United States
HOPE Research InstitutePhoenix, Arizona, United States
The Pain Center of ArizonaPhoenix, Arizona, United States
The Pain Center of ArizonaPhoenix, Arizona, United States
Genova Clinical ResearchTucson, Arizona, United States
Larry Watkins, M.D. (Private Practice)Little Rock, Arkansas, United States
Lynn Institute of the OzarksLittle Rock, Arkansas, United States
Hearne Family Practice ClinicLittle Rock, Arkansas, United States
Center for Clinical Research, IncCarmichael, California, United States
Community Medical ProvidersClovis, California, United States

+ 134 more locations — full list on the registry record.

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Gulf ShoresChandlerPhoenixTucson

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →